Document is current

Article History

Accepted: 22 January 2024

First Online: 29 February 2024

Declarations

:

: Medical writing and editorial support for the preparation of this manuscript was provided by Simpson Healthcare and funded by Galderma Laboratories. The sponsor of the open access fee is Galderma Laboratories.

: The authors declare the following potential conflicts. S.R.D. serves as a consultant for Galderma. In addition, he serves in multiple other leadership and industry roles unrelated to this product. H.B. has served as an advisor and speaker for Galderma, Bausch, Sun, Almirall, and EPI, as well as an advisor and investigator to Sol-Gel Technologies Ltd. J.Q.D.R. is a consultant, researcher, and speaker for Galderma, Almirall, Bausch Health (Ortho), Beiersdorf, BioPharmX, Cassiopeia, EPI Health, Ferndale, Leo Pharma, LaRoche-Posay, L’Oreal, Main Pharma, SolGel, Sun Pharma, and Vyne. R.L.G. is a cofounder, scientific advisor, and consultant, has equity in MatriSys Biosciences, and is a consultant for Galderma. N.B. is a consultant for Abbvie, Almirall, Arcutis, Beiersdorf, Biofrontera, BMS, BI, Cara, Dermavant, EPI Health, Ferndale, Galderma, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Ortho, Pfizer, Regeneron, Sanofi, SunPharma, and Verrica. J.C.H. has served as consultant for Cutera, Almirall, Sun, LaRoche-Posay, Ortho, EPI, BioPharmX, Cassiopeia, Cutanea, Vyne, Galderma, Dermira and Sol-Gel Technologies Ltd.; a speaker for Almirall, Ortho, EPI, Vyne, and Galderma; and an advisory board member for EPI, Cassiopeia, Cutanea, Vyne, and Galderma. J.P.Y. is an employee of Galderma Laboratories. L.S.G. is an advisor/investigator and/or consultant for Galderma, Ortho Derm, EPI Health, Vyne, Novartis, Sun, and Cutera.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors assisted in the drafting of and critical revision of this manuscript. They have all read and approved the final version of the manuscript as well.